HM10660A, a long-acting hIFN-alpha-2b, is a potent candidate for the treatment of hepatitis C through an enhanced biological half-life
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Bae, Sungmin | - |
dc.contributor.author | Sim, Taehoon | - |
dc.contributor.author | Lim, Chaemin | - |
dc.contributor.author | Kim, Daejin | - |
dc.contributor.author | Lee, Jongsoo | - |
dc.contributor.author | Park, Youngjin | - |
dc.contributor.author | Jung, Sungyoub | - |
dc.contributor.author | Choi, Inyoung | - |
dc.contributor.author | Kwon, Sechang | - |
dc.contributor.author | Oh, Kyung Taek | - |
dc.date.available | 2019-03-08T06:58:38Z | - |
dc.date.issued | 2017-12 | - |
dc.identifier.issn | 0378-5173 | - |
dc.identifier.issn | 1873-3476 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/cau/handle/2019.sw.cau/3484 | - |
dc.description.abstract | Interferon-alpha (IFN-alpha) has been widely used for the treatment of infections due to the hepatitis C virus (HCV). Because of the short half-life of IFN-alpha in serum, it must be administered three times per week. To increase the half-life of IFN-alpha, the immunoglobulin G4 (IgG4) Fc fragment (HMC001) was conjugated with human IFN-alpha-2b to develop a long-acting IFN-alpha-2b, HM10660A. An analysis of the antiviral efficacy of HM10660A in a human hepatocyte-engrafted mouse model found that HM10660A reduced serum HCV titers more effectively than a commercially available peginterferon alpha-2a (PEGASYS (R)) and IFN-alpha-2b. Pharmacokinetic (PK) and pharmacodynamic (PD) studies of HM10660A using monkeys demonstrated that the half-life of HM10660A was approximately 2-fold longer than commercially available peginterferon alpha-2a, which is approved for a once-weekly regimen. Moreover, the IFN-mediated induction profiles of neopterin and 2', 5'-oligoadenylate synthase (OAS) in normal cynomolgus monkeys indicated that HM10660A had enhanced antiviral activity and a prolonged duration of action compared with peginterferon alpha-2a. Considering the improved PK and PD properties, HM10660A can most likely be dosed every two or four weeks, providing superior antiviral efficacy and convenience for patients with HCV. | - |
dc.format.extent | 8 | - |
dc.language | 영어 | - |
dc.language.iso | ENG | - |
dc.publisher | ELSEVIER SCIENCE BV | - |
dc.title | HM10660A, a long-acting hIFN-alpha-2b, is a potent candidate for the treatment of hepatitis C through an enhanced biological half-life | - |
dc.type | Article | - |
dc.identifier.doi | 10.1016/j.ijpharm.2017.09.074 | - |
dc.identifier.bibliographicCitation | INTERNATIONAL JOURNAL OF PHARMACEUTICS, v.534, no.1-2, pp 89 - 96 | - |
dc.description.isOpenAccess | N | - |
dc.identifier.wosid | 000415579600010 | - |
dc.identifier.scopusid | 2-s2.0-85031108281 | - |
dc.citation.endPage | 96 | - |
dc.citation.number | 1-2 | - |
dc.citation.startPage | 89 | - |
dc.citation.title | INTERNATIONAL JOURNAL OF PHARMACEUTICS | - |
dc.citation.volume | 534 | - |
dc.type.docType | Article | - |
dc.publisher.location | 네델란드 | - |
dc.subject.keywordAuthor | Interferon-alpha (IFN-alpha) | - |
dc.subject.keywordAuthor | Hepatitis C virus (HCV) | - |
dc.subject.keywordAuthor | IFN-alpha-2b | - |
dc.subject.keywordAuthor | Cytokine | - |
dc.subject.keywordAuthor | Human IgG4 | - |
dc.subject.keywordAuthor | HM10660A | - |
dc.subject.keywordPlus | NEONATAL FC-RECEPTOR | - |
dc.subject.keywordPlus | HUMAN IGG1 | - |
dc.subject.keywordPlus | CYNOMOLGUS MONKEYS | - |
dc.subject.keywordPlus | FUSION PROTEINS | - |
dc.subject.keywordPlus | INTERFERON | - |
dc.subject.keywordPlus | PHARMACOKINETICS | - |
dc.subject.keywordPlus | ANTIBODY | - |
dc.subject.keywordPlus | RIBAVIRIN | - |
dc.subject.keywordPlus | AFFINITY | - |
dc.subject.keywordPlus | PHARMACODYNAMICS | - |
dc.relation.journalResearchArea | Pharmacology & Pharmacy | - |
dc.relation.journalWebOfScienceCategory | Pharmacology & Pharmacy | - |
dc.description.journalRegisteredClass | sci | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
84, Heukseok-ro, Dongjak-gu, Seoul, Republic of Korea (06974)02-820-6194
COPYRIGHT 2019 Chung-Ang University All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.